These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2570087)

  • 1. Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels.
    Garver DL
    J Clin Psychopharmacol; 1989 Aug; 9(4):277-81. PubMed ID: 2570087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
    Harris PQ; Brown SJ; Friedman MJ; Bacopoulos NG
    Biol Psychiatry; 1984 Jun; 19(6):849-60. PubMed ID: 6146355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin and neuroleptic drugs.
    Green AI; Brown WA
    Neurol Clin; 1988 Feb; 6(1):213-23. PubMed ID: 2898095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population.
    Dunlop SR; Shea PA; Hendrie HC
    Biol Psychiatry; 1982 Aug; 17(8):929-36. PubMed ID: 6126231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of neuroleptic psychopharmacology.
    Ortiz A; Gershon S
    J Clin Psychiatry; 1986 May; 47 Suppl():3-11. PubMed ID: 2871013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
    Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
    Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological treatment of delusional depression].
    Amore M; Giordani L; Giorgetti G; Zazzeri N
    Minerva Psichiatr; 1996 Mar; 37(1):29-33. PubMed ID: 8804200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood level monitoring of antipsychotics and antidepressants.
    Javaid JI; Janicak PG; Holland D
    Psychiatr Med; 1991; 9(1):163-87. PubMed ID: 1673256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.
    Ereshefsky L
    J Clin Psychiatry; 1999; 60 Suppl 10():20-30. PubMed ID: 10340684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L; Saklad SR; Jann MW; Davis CM; Richards A; Seidel DR
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
    Bergemann N; Kopitz J; Kress KR; Frick A
    Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.